centanafadine + escitalopram

**Centanafadine + escitalopram** is an investigational oral combination consisting of centanafadine, a triple reuptake inhibitor targeting norepinephrine, dopamine, and serotonin transporters, and escitalopram, a selective serotonin reuptake inhibitor (SSRI). This combination is studied for the treatment of major depressive disorder in adults who have had an inadequate response to previous antidepressant therapies. Centanafadine acts by inhibiting the reuptake of norepinephrine, dopamine, and serotonin, while escitalopram increases synaptic serotonin by selectively inhibiting its reuptake. The combination is currently evaluated for its efficacy, safety, and tolerability in clinical trials for major depressive disorder[1][2][3][4][5][6].